mRNA-4157/V940

mRNA-4157/V940 is an experimental drug being investigated for use against skin and pancreatic cancer.[1][2]

History

mRNA-4157/V940 was initially developed by Moderna. In 2022 Moderna and Merck jointly put mRNA-4157/V940 into clinical trials in combination with Merck's cancer immunotherapy drug pembrolizumab.[3][4][5] In February 2023, the Food and Drug Administration granted mRNA-4157/V940 breakthrough status.

Mechanism of action

mRNA-4157/V940 is an mRNA based cancer vaccine. When used, it produces one of several dozen possible abnormal proteins commonly found in cancerous tissues. The production of those proteins is intended to invoke an immune response. mRNA-4157/V940 is given to patients after their tumors have been sequenced and abnormal proteins identified. The drug is then customized to match a patient's tumor, which makes it an example of personalized medicine.

References
  1. "Precision medicine meets cancer vaccines". Nature Medicine. 16 June 2023. Retrieved 6 July 2023.
  2. Bafaloukos, Dimitrios (2023). "Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects". Vaccines. 11 (3): 636. doi:10.3390/vaccines11030636. PMC 10057252. PMID 36992220.
  3. Markman, Jon (10 May 2023). "Moderna's Revolutionary Cancer Vaccine Sets Investors Abuzz". Forbes. Retrieved 6 July 2023.
  4. Steenhuysen, Julie (16 April 2023). "Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return". Reuters. Retrieved 6 July 2023.
  5. "Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA® (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial" (Press release). Merck. Retrieved 2023-07-06.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.